摘要
目的 探讨质子泵抑制剂（兰索拉唑和雷贝拉唑）对冠心病患者双重抗血小板治疗作用的影响.方法 选择接受双重抗血小板治疗的冠心病患者181例,其中66例患者未使用质子泵抑制剂治疗（对照组）,65例患者使用兰索拉唑治疗（兰索拉唑组）,50例患者使用雷贝拉唑治疗（雷贝拉唑组）.入选患者均服用阿司匹林100 mg/d和氯吡格雷75 mg/d.检测各组血小板聚集阈值（PATI）、二磷酸腺苷（ADP）和胶原蛋白诱导的血小板聚集率等指标.结果 对照组ADP-PATI为（3.47±0.96）μmol/L,兰索拉唑组为（3.28±1.05）μmol/L,雷贝拉唑组为（3.32±0.83）μmol/L,各组间比较差异无统计学意义（P＞0.05）.胶原蛋白-PATI、血小板聚集率各组间比较差异亦无统计学意义（P＞0.05）.结论 冠心病患者双重抗血小板治疗期间,联合应用兰索拉唑或雷贝拉唑治疗并不影响抗血小板作用.
Objective To investigate the influence of proton pump inhibitors （lansoprazole and rabeprazole） on dual-antiplatelet therapy （DAPT） in patients with coronary heart disease.Methods One hundred and eighty-one cases of coronary heart disease with DAPT were selected,and they were divided into control group （66 cases,no proton pump inhibitors administered）,lansoprazole group （65 cases,lansoprazole administered） and rabeprazole group （50 cases,rabeprazole administered）.100 mg/day of aspirin and 75 mg/day of clopidogrel were concomitantly used in all patients.Platelet aggregation rate,platelet aggregation threshold index （PATI） and adenosine diphosphate （ADP） was measured.Results The ADP-PATI in control group was （3.47 ± 0.96） μ mol/L,lansoprazole group was （3.28 ± 1.05） μ mol/L,rabeprazole group was （3.32 ±0.83） μ mol/L,and there was no statistically significant difference among three groups （P〉0.05）.There was also no statistically significant difference in platelet aggregation rate and collagen-PATI among three groups （P 〉 0.05）.Conclusion In patients with coronary artery disease,the concomitant use of lansoprazole or rabeprazole does not affect antiplatelet action during DAPT.
出处
《中国医师进修杂志》
2013年第31期7-9,共3页
Chinese Journal of Postgraduates of Medicine
